Lucinda Bateman

Lucinda Bateman (Cindy Bateman), MD, is an ME/CFS doctor and researcher. She founded and is Chief Medical Officer of the Bateman Horne Center of Excellence for ME/CFS and Fibromyalgia in Salt Lake City, Utah.

Dr. Bateman was one of the authors of the 2011 case definition, International Consensus Criteria, and was one of the experts on the "Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome" that was convened for the 2015 Institute of Medicine report.

Open Letter to The Lancet
Two open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. In 2016, Dr. Bateman, along with 41 colleagues in the ME/CFS field, signed the second letter.
 * 10 February 2016, An open letter to The Lancet, again - Virology blog

Notable studies

 * 2015, Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome. Abstract
 * 2015, Chronic fatigue syndrome and co-morbid and consequent conditions: evidence from a multi-site clinical epidemiology study. Abstract
 * 2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome."Abstract: 'A Phase III prospective, double-blind, randomized, placebo-controlled trial comparing twice weekly IV rintatolimod versus placebo was conducted in 234 subjects with long-standing, debilitating CFS/ME at 12 sites. The primary endpoint was the intra-patient change from baseline at Week 40 in exercise tolerance (ET). Secondary endpoints included concomitant drug usage, the Karnofsky Performance Score (KPS), Activities of Daily Living (ADL), and Vitality Score (SF 36). Subjects receiving rintatolimod for 40 weeks improved intra-patient placebo-adjusted ET 21.3% (p = 0.047) from baseline in an intention-to-treat analysis. Correction for subjects with reduced dosing compliance increased placebo-adjusted ET improvement to 28% (p = 0.022). The improvement observed represents approximately twice the minimum considered medically significant by regulatory agencies. The rintatolimod cohort vs. placebo also reduced dependence on drugs commonly used by patients in an attempt to alleviate the symptoms of CFS/ME (p = 0.048). Placebo subjects crossed-over to receive rintatolimod demonstrated an intra-patient improvement in ET performance at 24 weeks of 39% (p = 0.04). Rintatolimod at 400 mg twice weekly was generally well-tolerated."

Clinic location
The Bateman Horne Center 1002 E. South Temple St., Suite 408, Salt Lake City, Utah 84102 1-801-359-7400

Talks & interviews

 * 2016, Simple But Effective Tools for Management of ME/CFS and FM - Lucinda Bateman, MD
 * 2016, BHC Wings to Fly - Dr. Bateman

Webinars
Science to patients / Wetenschap voor patienten


 * 2015, 68. Introduction and diagnosis / intriductie en diagnose - Dr. Lucinda Bateman


 * 2015, 69. Autoimmunity in ME/cfs / Auto-immuniteit bij ME/cvs - Dr. Lucinda Bateman


 * 2015, 70. Neuroinflammation and ME/cfs / Neuro-inflammatie en ME/cvs - Dr. Lucinda Bateman


 * 2015, 71. ME/cfs and the Brain/ ME/cvs en de hersenen - Dr. Lucinda Bateman


 * 2015, 72. Gene-expression and exercise / gen-expressie en inspanning - Dr. Lucinda Bateman


 * 2015, 73. FAQs part 1 / Veel gestelde vragen deel 1 - Dr. Lucinda Bateman


 * 2015, 74. FAQs part 2 / Veel gestelde vragen deel 2 - Dr. Lucinda Bateman

Solve ME/CFS Initiative


 * Apr 17, 2015 "Will SEID Diagnostic Criteria Improve Diagnosis and Treatment?"
 * Nov 14, 2014 "Can ME CFS and Fibromyalgia Research Help You Sleep?"

Online presence

 * PubMed - Lucinda Bateman
 * Twitter
 * Facebook
 * Website
 * YouTube

Learn more

 * Cort Johnson - Lucinda Bateman profile
 * Lucinda Bateman